Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Treatment Resistant Depression
Interventions: Lithium, Placebo, Ketamine; Drug
Lead sponsor: William V. Bobo, M.D.; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Interventions: ARC 1779 Placebo, ARC1779 Injection; Drug
Lead sponsor: Archemix Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 7
States / cities: Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more

Conditions: Schizophrenia
Interventions: Infliximab, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more

Conditions: HIV Infections
Interventions: VH4524184, Midazolam, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: LPX-TI641; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Coronary Disease
Interventions: RUC-4 Compound; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3526318, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 35
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 28 more

Conditions: Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions: Amitriptyline, Escitalopram, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo (for Ramucirumab), Docetaxel; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 97
States / cities: Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more

Conditions: Plaque Psoriasis
Interventions: PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Postoperative Pain, Spinal Fusion
Interventions: Local infiltration with 0.25% bupivacaine and epinephrine, Placebo of equal volume injectable saline; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-Traumatic Stress Disorders
Interventions: individualized Transcranial Magnetic Stimulation; Device
Lead sponsor: 72nd Medical Group, Tinker Air Force Base; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cancer
Interventions: Insertion of Pressure Equalization (PE) Tubes, Sodium Thiosulfate (STS), Saline (Placebo), Cisplatin; Procedure · Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder
Interventions: Prazosin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Knee Osteoarthritis
Interventions: DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Stress
Interventions: Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI; Drug · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Gastroparesis
Interventions: GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more

Conditions: Premature Birth, Antibiotics, Neurodevelopment
Interventions: Ampicillin, Gentamicin, Placebo; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: San Diego, California • New Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Respiratory Tract Infections
Interventions: PF-04287881, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: FDC fianlimab+cemiplimab, Cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 14 more

Conditions: Atypical Facial Pain, Persistent Idiopathic Facial Pain, Atypical Trigeminal Neuralgia, Neuropathic Orofacial Pain, Neuropathic Facial Pain
Interventions: ATNC05, Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Glabellar Lines, Lateral Canthal Lines
Interventions: MT10109L, Placebo; Drug
Lead sponsor: Medy-Tox; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 9
States / cities: Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more

Search by objective public record fields.

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Anti-Inflammatory Challenge in Schizophrenia

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

Functional Dyspepsia Treatment Trial

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Postoperative Pain Control Using Local Wound Infiltration in Adolescent Idiopathic Surgery

To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

NICU Antibiotics and Outcomes (NANO) Follow-up Study

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)